The trajectory of companies tied to Sildenafil's past presents a intricate investment picture . While the initial success generated substantial profits , generic competition have significantly eroded sales . Investing in associated pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving medical trends , and